Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.65 |
| ▸ | NPC1 | O15118 | 5/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | SLC9A1 | P19634 | 8/20 | 0.59 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3428426 | 0.79 | NPC1 (1.00) | RAB9ANPC1MAPTSLC9A1GRM2 | |
| SCHEMBL13068570 | 0.78 | RAB9A (0.72) | RAB9ANPC1MAPTSLC9A1GRM2 | |
| SCHEMBL14722565 | 0.78 | RAB9A (0.68) | RAB9ANPC1MAPTSLC9A1MEN1 | |
| SCHEMBL5696411 | 0.75 | SLC9A1 (0.44) | RAB9ANPC1MAPTSLC9A1GRM2 | |
| SCHEMBL2734889 | 0.75 | GRM2 (1.00) | RAB9ANPC1MAPTSLC9A1GRM2 | |
| SCHEMBL14796568 | 0.75 | SLC9A1 (0.79) | RAB9ANPC1MAPTSLC9A1GRM2 | |
| SCHEMBL14477218 | 0.73 | TSHR (0.60) | RAB9ANPC1MAPTSLC9A1GRM2 | |
| SCHEMBL6031035 | 0.73 | SMN1; SMN2 (0.74) | RAB9ANPC1MAPTLMNAL3MBTL1 | |
| SCHEMBL13686677 | 0.72 | SLC9A1 (0.69) | RAB9ANPC1MAPTSLC9A1MEN1 | |
| SCHEMBL4222242 | 0.72 | SLC9A1 (0.68) | RAB9ANPC1MAPTSLC9A1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110097269-A1 | PHENYLOXYANILINE DERIVATIVES | LEHMANN LUTZ | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110097269-A1 | PHENYLOXYANILINE DERIVATIVES | PNMT, PAH, NAT1 | RAB9A 3645/4885NPC1 3813/4885MAPT 1608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.